GlaxoSmithKline plc (GSK) is a science-led multinational pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in London, United Kingdom. It is one of the world's largest pharmaceutical companies measured by drug sales. GSK has a portfolio of products for major disease areas including asthma, cancer, virus control, infections, mental health, diabetes, and digestive conditions. Our products are used by millions of people around the world, helping them to do more, feel better and live longer. We are one of the few healthcare companies researching medicines and vaccines for the World Health Organisation's three priority diseases - HIV/AIDS, tuberculosis and malaria.

Research is vitally important to the success of our business (we spent just under £4 billion in 2012 in our search to develop new medicines, vaccines and innovative consumer products.) We are already heavily committed to engaging with scientists external to GSK and IMI has become an important way to further this. The K4DD consortium is addressing a major opportunity to engage some of the best scientists in Europe to work on the challenge of understanding more about how understanding receptor kinetics can help in our collective quest to more effectively and efficiently develop new drugs for unmet medical needs.